Delayed administration of a potent cyclin dependent kinase and glycogen synthase kinase 3 β inhibitor produces long-term neuroprotection in a hypoxia-ischemia model of brain injury

Neuroscience

Volumn 155, Issue 3, 2008, Pages 864-875

  Cowper Smith, C D ^a   Anger, G J A ^a   Magal, E ^b   Norman, M H ^b   Robertson, G S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b AMGEN INC   (United States)

Author keywords

apoptosis; excitotoxicity; necrosis; neuroprotection; stroke

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA NUCLEOTIDYLEXOTRANSFERASE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HYPOXIA; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CELL COUNT; CELL LOSS; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; FEMALE; HIPPOCAMPUS; IC 50; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR COORDINATION; MOUSE; NERVE CELL; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECTUM TEMPERATURE; THERAPY DELAY;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; CELL DEATH; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HYPOXIA-ISCHEMIA, BRAIN; IN SITU NICK-END LABELING; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; TIME FACTORS;

EID: 49449085225     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.05.051     Document Type: Article

References (54)

1. Alvira D., et al. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res 40 (2006) 251-258
2. Baird A.E., et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 41 (1997) 581-589
3. Bajaj N.P., et al. Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis. Neurosci Lett 245 (1998) 45-48
4. Belayev L., et al. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 26 (1995) 2313-2319 discussion 2319-2320
5. Bhat R.V., et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 97 (2000) 11074-11079
6. Camins A., et al. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19 (2006) 453-460
7. Corbett D., and Nurse S. The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog Neurobiol 54 (1998) 531-548
8. Cruz J.C., and Tsai L.H. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10 (2004) 452-458
9. Dereski M.O., et al. The heterogeneous temporal evolution of focal ischemic neuronal damage in the rat. Acta Neuropathol (Berl) 85 (1993) 327-333
10. Dhavan R., and Tsai L.H. A decade of CDK5. Nat Rev Mol Cell Biol 2 (2001) 749-759
11. Di Giovanni S., et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A 102 (2005) 8333-8338
12. Dirnagl U., et al. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22 (1999) 391-397
13. El-Khodor B.F., et al. Ectopic expression of cell cycle markers in models of induced programmed cell death in dopamine neurons of the rat substantia nigra pars compacta. Exp Neurol 179 (2003) 17-27
14. Gray N., et al. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 6 (1999) 859-875
15. Hamdane M., et al. p25/Cdk5-Mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci 118 (2005) 1291-1298
16. Heady L., et al. Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations. J Med Chem 49 (2006) 5141-5153
17. Hever G., Norman M., Wang J., Zhang M., Jiao S., Louis J., and Magal E. Cdk5 inhibition as a target for neuroprotection in rat model of middle cerebral artery occlusion (2003), Society for Neuroscience, Washington, DC
18. Hu B.R., et al. Involvement of caspase-3 in cell death after hypoxia-ischemia declines during brain maturation. J Cereb Blood Flow Metab 20 (2000) 1294-1300
19. Ino H., and Chiba T. Cyclin-dependent kinase 4 and cyclin D1 are required for excitotoxin-induced neuronal cell death in vivo. J Neurosci 21 (2001) 6086-6094
20. Ishizawa T., et al. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 163 (2003) 1057-1067
21. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29 (2004) 95-102
22. Jope R.S., et al. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32 (2007) 577-595
23. Kitagawa K., et al. Species differences in fodrin proteolysis in the ischemic brain. J Neurosci Res 55 (1999) 643-649
24. Knockaert M., et al. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23 (2002) 417-425
25. Kuan C.Y., et al. Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain. J Neurosci 24 (2004) 10763-10772
26. Lee M.S., et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
27. Leist M., and Nicotera P. Apoptosis, excitotoxicity, and neuropathology. Exp Cell Res 239 (1998) 183-201
28. Lew J., Beaudette K., Litwin C.M.E., and Wang J.H. Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem 267 (1992) 13383-13390
29. Lubics A., et al. Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic-ischemic injury. Behav Brain Res 157 (2005) 157-165
30. Martin R.L., Lloyd H.G., and Cowan A.I. The early events of oxygen and glucose deprivation: setting the scene for neuronal death?. Trends Neurosci 6 (1994) 251-257
31. Monaco III E.A., and Vallano M.L. Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease. Front Biosci 10 (2005) 143-159
32. Nguyen M.D., et al. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci 23 (2003) 2131-2140
33. Nguyen M.D., et al. Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 9 (2002) 1294-1306
34. Osuga H., et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A 97 (2000) 10254-10259
35. Park D.S., et al. Cell cycle regulators in neuronal death evoked by excitotoxic stress: implications for neurodegeneration and its treatment. Neurobiol Aging 21 (2000) 771-781
36. Patrick G.N., et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
37. Peineau S., et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53 (2007) 703-717
38. Peters A., et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 28 (2004) 143-180
39. Rashidian J., et al. Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo. Proc Natl Acad Sci U S A 102 (2005) 14080-14085
40. Rashidian J., et al. Cell cycle machinery and stroke. Biochim Biophys Acta 1772 (2007) 484-493
41. Rice III J.E., et al. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 9 (1981) 131-141
42. Shelton S.B., and Johnson G.V. Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem 88 (2004) 1313-1326
43. Sidhu R.S., et al. Nuclear condensation and fragmentation following cerebral hypoxia-ischemia occurs more frequently in immature than older rats. Neurosci Lett 223 (1997) 129-132
44. Smith P.D., et al. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26 (2006) 440-447
45. Trimarchi J.M., and Lees J.A. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3 (2002) 11-20
46. Valtysson J., et al. Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation. Acta Neurochir (Wien) 129 (1994) 58-63
47. Vannucci S.J., and Hagberg H. Hypoxia-ischemia in the immature brain. J Exp Biol 207 (2004) 3149-3154
48. Wang F., et al. Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J Cereb Blood Flow Metab 22 (2002) 171-182
49. Wang J., et al. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat Neurosci 6 (2003) 1039-1047
50. Weishaupt J.H., et al. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol Cell Neurosci 24 (2003) 489-502
51. Wen Y., et al. Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats. J Biol Chem 279 (2004) 22684-22692
52. Wen Y., et al. Cell-cycle regulators are involved in transient cerebral ischemia induced neuronal apoptosis in female rats. FEBS Lett 579 (2005) 4591-4599
53. Zhu C., et al. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ 12 (2005) 162-176
54. Zhu C., et al. Different apoptotic mechanisms are activated in male and female brains after neonatal hypoxia-ischaemia. J Neurochem 96 (2006) 1016-1027